{"DataElement":{"publicId":"5326789","version":"1","preferredName":"Menstrual Cycle End Reason Tamoxifen Citrate Data Unknown Text","preferredDefinition":"A checkbox for information related to the reason the menstrual cycle ends from tamoxifen.","longName":"MENCYC_END_RSN_TAMOX_TXT","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"5326773","version":"1","preferredName":"Menstrual Cycle End Reason Tamoxifen Citrate","preferredDefinition":"The Menstrual Cycle involves regularly recurring hormonal changes and physiologic endometrial changes during the reproductive period in human females, and some primates, and culminates in partial sloughing of the endometrium (menstruation) in the absence of fertilization. For most women, one cycle takes 28 days. (NCI)_The point or place at which something terminates in time, space, or extent._An explanation of the cause of some phenomenon or action._The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","longName":"MENCYC_END_RSN_TAMOX","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"2442660","version":"1","preferredName":"Menstrual Cycle","preferredDefinition":"Regularly recurring physiologic changes in the endometrium during the reproductive period in human females, and some primates, and culminating in partial sloughing of the endometrium (menstruation) in the absence of fertilization. The hormonal changes that lead up to a woman's having a period. For most women, one cycle takes 28 days.","longName":"C16838","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Menstrual Cycle","conceptCode":"C16838","definition":"The Menstrual Cycle involves regularly recurring hormonal changes and physiologic endometrial changes during the reproductive period in human females, and some primates, and culminates in partial sloughing of the endometrium (menstruation) in the absence of fertilization. For most women, one cycle takes 28 days. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"09046428-5207-6C1D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2006-01-06","modifiedBy":"ONEDATA","dateModified":"2006-01-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5326771","version":"1","preferredName":"End Reason Tamoxifen Citrate","preferredDefinition":"The point or place at which something terminates in time, space, or extent.:An explanation of the cause of some phenomenon or action.:The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","longName":"C25496:CL052595:C855","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"End","conceptCode":"C25496","definition":"The point or place at which something terminates in time, space, or extent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Reason","conceptCode":"CL052595","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_META_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3657B776-9562-C9E2-E050-BB89AD43381E","latestVersionIndicator":"Yes","beginDate":"2016-06-28","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-06-28","modifiedBy":"ONEDATA","dateModified":"2016-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008542","version":"1","preferredName":"Reproduction","preferredDefinition":"the patient's ability to conceive or nurse offspring and/or their current reproductive status.","longName":"REPRODUCTION","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227DAE6-EC15-4A7D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3657B776-9573-C9E2-E050-BB89AD43381E","latestVersionIndicator":"Yes","beginDate":"2016-06-28","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-06-28","modifiedBy":"MORENOC","dateModified":"2017-08-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2200608","version":"1","preferredName":"Data Unknown Text","preferredDefinition":"a single character text field to record data.","longName":"DATA_UNKNOWN_TEXT","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234203","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F89B-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1B9DBEC-1A57-2AD7-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-07","modifiedBy":"ALAIS","dateModified":"2009-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Tamoxifen","type":"Preferred Question Text","description":"Tamoxifen","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"365815B2-AB4B-72BB-E050-BB89AD430FEE","latestVersionIndicator":"Yes","beginDate":"2016-06-28","endDate":null,"createdBy":"MORENOC","dateCreated":"2016-06-28","modifiedBy":"MORENOC","dateModified":"2017-08-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}